PRESS-RELEASE filed Sep 10, 2026 at 06:01 ET
Axogen priced an underwritten public offering of 4,910,000 shares at $42.50 per share, expected to raise ~$208.7M in gross proceeds. The funds are primarily earmarked to finance the cash consideration for the previously announced BioCircuit Technologies acquisition, with any remainder for general corporate purposes. The offering is not conditioned on the acquisition closing, creating a scenario where Axogen could hold a large cash balance if the deal falls through, but the immediate effect is significant dilution for existing shareholders.